Navigation Links
Amerigen Pharmaceuticals and VIWA Pharmaceutical Company Today Jointly Announce the Signing of a Memorandum of Understanding (MOU) Setting Out Their Intention to Establish a Joint Venture to Develop and Register a Range of Branded Generic Medicines
Date:1/11/2012

EAST BRUNSWICK, N.J. and HANGZHOU, China, Jan. 11, 2012 /PRNewswire/ -- Amerigen Pharmaceuticals Limited and VIWA Pharmaceutical Company Limited today jointly announce the signing of a memorandum of understanding (MOU) setting out their intention to establish a joint venture to develop and register a range of branded generic medicines for sale in China. It is anticipated that the products, once approved, would be manufactured at Amerigen's SFDA and US FDA approved finished dose plant in Suzhou, China, with marketing and sales undertaken either by a Chinese affiliate of VIWA or a third party. Jonathan Embleton, Amerigen's Chief Business Officer commented, "We look forward to working with VIWA to bring some first time and technically sophisticated generic products to Chinese patients at more affordable prices, without compromising on quality."

Jack H. Ye, VIWA's managing director, added, "Combining Amerigen's development capabilities, manufacturing assets and access to products from Western markets with VIWA's access to API's and regulatory expertise in China should enable the joint venture to rapidly build up its product portfolio. This in turn will help accelerate VIWA's strategic thrust into the commercialization of finished pharmaceutical products in China."

John Lowry, Amerigen's President & CEO added, "The formation of this joint venture marks a first step by Amerigen to bring high quality and locally manufactured branded generic products to the Chinese market and, in the process, establish an Amerigen brand in China. We anticipate that additional collaborations will be established to further this strategy."

About Amerigen
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in East Brunswick, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese SFDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.

About VIWA
VIWA Pharmaceutical Company Limited is a member of the VIWA group of companies and is focused on the development, registration and commercialization of finished pharmaceutical products within China and for export to other markets. The VIWA group of companies also includes the Hangzhou VIWA Company Limited, a leading provider of active pharmaceutical ingredients, fine chemicals and intermediates to the global pharmaceutical, agrochemical and animal health industries.


'/>"/>
SOURCE Amerigen Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products
2. Amerigen Pharmaceuticals and Stason Pharmaceuticals Enter Into Collaboration Agreement for Development of Generic Oral Oncology Products
3. Amerigen Pharmaceuticals and the Shanghai Fosun Omni Pharmaceutical Company Enter Into Collaboration Agreement for the Development of Generic Oral Controlled Release Products
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... DIEGO , March 29, 2017  NuVasive, ... focused on transforming spine surgery with minimally disruptive, ... Administration (FDA) 510(k) clearance of the CoRoent® Small ... multiple contiguous levels in the cervical spine. This ... cage to be used at up to four ...
(Date:3/29/2017)... March 29, 2017 On March 28, the U.S. Food ... patients with relapsing forms of multiple sclerosis (MS) and ... drug approved by the FDA for PPMS. Ocrevus is ... "Multiple sclerosis can have a profound ... , M.D., director of the Division of Neurology Products ...
(Date:3/29/2017)... Connecticut , March 29, 2017 ... company Sectra (STO: SECT B) announces ... will install Sectra PACS in their healthcare enterprise. ... the Epic EMR, will enable access and sharing ... pathway. Additionally, UPHS and Sectra will enter into ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... ... with wearing oral braces. "The rubber bands used in conjunction with my braces ... I decided to design a way to prevent this problem." The O.B.S. was ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... of Pittsburgh now have easier access to the robotic-assisted total-hip and partial-knee ... Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started ...
(Date:3/28/2017)... ... 2017 , ... A recent Bellwether Education Partners’ report begins ... must first improve teacher preparation program design. It then asserts that teacher-education programs ... of input- and outcome-based research has failed to improve teacher education. , This ...
(Date:3/28/2017)... MN (PRWEB) , ... March 28, 2017 , ... ... (MRE), is pleased to be invited to the Siemens Healthineers annual customer ... professionals. The event will take place from March 27 - 31, 2017 ...
(Date:3/28/2017)... NY (PRWEB) , ... March 28, 2017 , ... ... process management software and services, is proud to announce it has joined the ... professional association representing the interests of chronically ill, disabled, and dying Americans of ...
Breaking Medicine News(10 mins):